Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

Blood

Volumn 94, Issue 10, 1999, Pages 3315-3324

  Niu, Chao ^b   Yan, Hua ^b   Yu, Ting ^b   Sun, Hui Ping ^b   Liu, Jian Xiang ^b   Xiu Song, Li ^b   Wu, Wen ^b   Zhang, Fen Qin ^b   Chen, Yu ^b   Zhou, Li ^b   Li, Jun Min ^b   Zeng, Xiao Ying ^b   Yang, Ren Rong Ou ^b   Yuan, Mi Man ^b   Ren, Mei Yu ^b   Gu, Feng Ying ^b   Cao, Qi ^b   Gu, Bo Wei ^b   Su, Xin Ying ^b   Chen, Guo Qiang ^b   Xiong, Shu Min ^b   Zhang, Ting Dong ^b   Waxman, Samuel ^b   Wang, Zhen Yi ^b   Chen, Zhu ^b   Hu, Jiong ^b   Shen, Zhi Xiang ^b   Chen, Sai Juan ^a   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; CANCER REGRESSION; CELL DIFFERENTIATION; DRUG EFFECT; FEMALE; FOLLOW UP; FUSION GENE; HUMAN; LEUKOCYTOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONITORING; PRIORITY JOURNAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033570955     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.10.3315.422k16_3315_3324     Document Type: Article

References (29)

1. Larson RA, Kondo K, Vardiman JW, Butler AE, Colomb HM, Rowley JD: Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76:827,1984
2. de The H, Chomienne, Lanotte M, Degos L, Dejean A: The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 347:558,1990
3. Tong JH, Dong S, Geng JP, Huang W, Wang ZY, Sun GL, Chen SJ, Chen Z, Larsen CJ, Berger R: Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants. Oncogene 7:311, 1992
4. Warrell RP Jr, de The H, Wang ZY, Degos L: Acute promyelocytic leukemia. N Engl J Med 329:177, 1993
5. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhao L, Gu LJ, Wang ZY: Use of all-trans retinoic acid in treatment of acute promyelocytic leukemia. Blood 72:567, 1988
6. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704, 1990
7. Zhang TD: Treatment of acute granulocytic leukemia with "Ai Ling No. 1" - Clinical analysis and experimental research. Chin J Integrated Chin West Med 4:19, 1984
8. Li YS, Zhang TD, Li CHW, Zhao XL, Wei ZHR, Tan W, Li RL, Mao YY: Traditional Chinese and Western Medicine in the treatment of 27 patients with malignant lymphoma. Chin J Oncol 10:61, 1988
9. Sun HD, Ma L, Hu XC, Zhang TD: Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrated Chin West Med 12:170, 1992
10. Zhang P, Wang SY, Hu LH, Shi FD, Qiu FQ, Hong GJ, Han XY, Yang HF, Sun YZ, Liu YP, Zhao J, Jin ZJ: Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 2:58, 1996
11. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345, 1997
12. 3) in the treatment of acute promyelocytic leukemia: II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354, 1997
13. Sun HP, Chen XW, Chen Y, Li XS, Shen ZX: Use of arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin J N Drugs Clin Remedies 18:41, 1999
14. Soignet SL, Maslak P, Wang ZG, Jhanwar, Calleja E, Dardashti LJ, Corso D, Deblasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:6, 1998
15. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052, 1996
16. Chen Z, Wang ZY, Chen SJ: Acute promyelocytic leukemia: Cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther 76:141, 1997
17. Kitamura K, Kiyoi H, Yoshida H, Tobita T, Takeshita A, Ohno R, Naoe T: New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: Clinical and basic studies for the next generation. Cancer Chemother Pharmacol 40:536, 1997 (suppl)
18. ISCN Guidelines for cancer cytogenetics (1995) Supplement to an international system for human cytogenetic nomenclature. Basel, Switzerland, Karger, 1995
19. Chen SJ, Chen Z, Chen A, Tong JH, Dong S, Wang Z, Waxman S, Zelent A: Occurrence of distinct PML-RARα fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogne 7:1223, 1992
20. Haferlach T, Winkemann M, Loffler H, Schoch R, Gassmann W, Fonatsch C, Schoch C, Poetsch M, Weber-Matthiesen K, Schlegelberger B: The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: A combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization. Blood 87:2459, 1996
21. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Pandolfi PP: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in PML and PML-RARα independent manner. Blood 92:1497, 1998
22. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H: Arsenic-inducing PML targeting onto nuclear bodies: Implications for the treatment of APL. Proc Natl Acad Sci USA 94:3978, 1997
23. Lee TC, Ho IC: Modulation of cellular antioxidant defense activities by sodium arsenite in human fibroblasts. Arch Toxicol 69:498, 1995
24. Wang TS, Shu YF, Liu YC, Jan KY, Huang H: Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 121:229, 1997
25. Moore DF, O'Callaghan CA, Berlyre G, Ogg CS, Davies HA, House IM, Henry JA: Acute arsenic poisoning: absence of polyneuropathy after treatment with 2,3-dimercaptopropanesulphonate (DMPS). J Neurol Neurosurg Psychiatry 57:1133, 1994
26. Kreppel H, Paepcke U, Thiermann H, Szinica L, Reichl FX, Singh PK, Jones MM: Therapeutic efficacy of new dimer-captosuccinic acid (DMSA) analogues in acute arsenic trioxide poisoning in mice. Arch Toxicol 67:580, 1993
27. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 94:10907, 1997
28. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H: Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91:4300, 1998
29. Shao WL, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124, 1998